Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Rilonacept

Nature Reviews Drug Discovery volume 7, pages 385–386 (2008)Cite this article

Abstract

In February 2008, rilonacept (Arcalyst; Regeneron), an interleukin 1 blocker, was approved by the US FDA for the treatment of a group of rare autoinflammatory diseases known as cryopyrin-associated periodic syndromes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The cryopyrin inflammasome and CAPS.

References

  1. Shinkai, K. et al. Cryopyrin-associated periodic syndromes and autoinflammation. Clin. Exp. Dermatol. 33, 1–9 (2008).

    CAS  PubMed  Google Scholar 

  2. Drenth, J. P. H. & van der Meer, J. W. M. The inflammasome — a linebacker of innate defense. N. Engl. J. Med. 355, 730–732 (2006).

    Article  CAS  Google Scholar 

  3. Hoffman, H. M. et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome. Nature Genet. 29, 301–305 (2001).

    Article  CAS  Google Scholar 

  4. Agostini, L. et al. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity 20, 319–325 (2004).

    Article  CAS  Google Scholar 

  5. Hawkins, P. N. et al. Interleukin-1-receptor antagonist in the Muckle–Wells syndrome. N. Engl. J. Med. 348, 2583–2584 (2003).

    Article  Google Scholar 

  6. Hoffman, H. M. et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779–1785 (2004).

    Article  CAS  Google Scholar 

  7. Economides, A. N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nature Med. 9, 47–52 (2003)

    Article  CAS  Google Scholar 

  8. Food and Drug Administration. FDA labelling information [online], (2008).

Download references

Author information

Authors and Affiliations

  1. Departments of Pediatrics and Medicine, Hal M. Hoffman is at the UCSD School of Medicine, 9500 Gilman Drive, La Jolla, California 92093-0635, USA. hahoffman@ucsd.edu,

    Hal M. Hoffman

  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Hal M. Hoffman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Hal M. Hoffmann is a consultant for Regeneron.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoffman, H., Yasothan, U. & Kirkpatrick, P. Rilonacept. Nat Rev Drug Discov 7, 385–386 (2008). https://doi.org/10.1038/nrd2579

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2579

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing